Pharma titans Bristol Myers Squibb (NYSE: BMY) and Merck (NYSE: MRK) both offer above-average dividend yields relative to their peers. What's more, Bristol has been hard at work applying cutting-edge tools such as gene editing, machine learning, and artificial intelligence to the construction and advancement of its plethora of pipeline candidates. With its shares trading at a paltry 2.45 times 2025 projected sales and its annualized dividend yield now at a healthy 3.6%, Bristol's stock definitely qualifies as a screaming buy -- especially for investors concerned about inflation.